By Jen Christensen Drugmaker Johnson & Johnson said Wednesday it had found a quality problem at a Baltimore plant helping manufacture its single-dose coronavirus vaccine under contract. The New York Times reported Wednesday. that workers at Emergent BioSolutions, the Baltimore plant that